Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
Neuroimaging in dementia: more than typical Alzheimer disease
Alzheimer disease (AD) is the most common cause of dementia. The prevailing theory of the
underlying pathology assumes amyloid accumulation followed by tau protein aggregation …
underlying pathology assumes amyloid accumulation followed by tau protein aggregation …
Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic
D Altomare, S Stampacchia, F Ribaldi… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background The key Alzheimer's disease (AD) biomarkers are traditionally measured with
techniques/exams that are either expensive (amyloid-positron emission tomography (PET) …
techniques/exams that are either expensive (amyloid-positron emission tomography (PET) …
Association of presynaptic loss with Alzheimer's disease and cognitive decline
Objective Increased presynaptic dysfunction measured by cerebrospinal fluid (CSF) growth‐
associated protein‐43 (GAP43) may be observed in Alzheimer's disease (AD), but how CSF …
associated protein‐43 (GAP43) may be observed in Alzheimer's disease (AD), but how CSF …
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …
Abnormal tau in amyloid PET negative individuals
B Yoon, T Guo, K Provost, D Korman, TJ Ward… - Neurobiology of …, 2022 - Elsevier
We examined the characteristics of individuals with biomarker evidence of tauopathy but
without β-amyloid (Aβ)(A-T+) in relation to individuals with (A+ T+) and without (AT-) …
without β-amyloid (Aβ)(A-T+) in relation to individuals with (A+ T+) and without (AT-) …
The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline
C Boccalini, F Ribaldi, I Hristovska… - Alzheimer's & …, 2024 - Wiley Online Library
INTRODUCTION Tau and neurodegeneration strongly correlate with cognitive impairment,
as compared to amyloid. However, their contribution in explaining cognition and predicting …
as compared to amyloid. However, their contribution in explaining cognition and predicting …
Robust EEG based biomarkers to detect Alzheimer's disease
Biomarkers to detect Alzheimer's disease (AD) would enable patients to gain access to
appropriate services and may facilitate the development of new therapies. Given the large …
appropriate services and may facilitate the development of new therapies. Given the large …
Molecular imaging approaches in dementia
The increasing prevalence of dementia worldwide places a high demand on healthcare
providers to perform a diagnostic work-up in relatively early stages of the disease, given that …
providers to perform a diagnostic work-up in relatively early stages of the disease, given that …
What's the cut-point?: a systematic investigation of tau PET thresholding methods
Background Tau positron emission tomography (PET) is increasing in popularity for
biomarker characterization of Alzheimer's disease (AD), and recent frameworks rely on tau …
biomarker characterization of Alzheimer's disease (AD), and recent frameworks rely on tau …